Radiprodil is under clinical development by Neurvati Neurosciences and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase I drugs for Neurodegenerative Diseases have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Radiprodil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radiprodil is under development for the treatment of GRIN-related disorder. It acts by targeting NMDA-2B receptor. It is administered in the from of granules and suspension through oral route.
Neurvati Neurosciences overview
Neurvati Neurosciences is involved in neuroscience product development and treatment options. Neurvati Neurosciences is headquartered in Wilmington, Delaware, the US.
For a complete picture of Radiprodil’s drug-specific PTSR and LoA scores, buy the report here.